地拉罗司去铁的效果

The U.S. Food and Drug Administration (FDA) approved a new indication on January 23 for the treatment of chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia (NTDT). The launch of deferasirox has also attracted much attention from patients. Today we will learn more about the iron-removing effect of deferasirox.

A multicenter, prospective clinical trial was conducted to evaluate the safety and efficacy of deferasirox (Enreg) in patients with low- or intermediate-risk-1 myelodysplastic syndrome (MDS). The study selected patients with serum ferritin ≥1000 μg/L, transfusion dependence and red blood cell transfusions ≥20U to be included. The starting dose of deferasirox (Enrige) is 20 mg/kg/d, which can be adjusted up to 40 mg/kg/d. A total of 176 patients were enrolled in the study, of whom 173 received treatment. 53% of patients completed 12 months of treatment (n = 91) with a 23% decrease in mean serum ferritin, 36.7% completed 2 years of treatment (N = 49), and 36.5% completed 3 years of treatment (N = 33). The study found that the reduction of serum ferritin was significantly positively correlated with the improvement of ALT (P <0.001). Baseline labile plasma iron (LPI) was elevated in 68 patients (39.3%). After 13 weeks, all patients with abnormal baseline LPI levels returned to normal. To explore the efficacy and safety of the iron chelator deferasirox (Enrige) in the treatment of iron overload in children with β-thalassemia major (β-TM).

Methods Twenty-four children with β-TM iron overload who received regular blood transfusions were randomly selected to participate in a clinical study of different doses of deferasirox, and the changes in serum ferritin (SF) and adverse reactions were investigated. The cardiac MRI T2 and liver MRI T2 values ​​of children who continued to take deferasirox for 5 years were compared with those of children who were treated with deferoxamine combined with deferiprone during the same period (control group). Results: The initial dose of deferasirox (Enrige) of 20 to 30 mg/kg per day had no obvious effect on children with iron overload. After the dose was increased to 30 to 40 mg/kg per day, the SF level dropped significantly (U=58, P0.01). The most common adverse reaction was an increase in serum liver transaminases, followed by a non-progressive increase in serum creatinine. The SF level of the 5-year continuous deferasirox treatment group was significantly lower than that of the control group (1748±481 ng/mL vs 3462±1744 ng/mL, P0.05); the liver MRI T2 value was significantly higher than that of the control group (8.5±2.9 ms vs 2.7±1.9 ms, P0.01). There was no statistically significant difference in the mean cardiac MRI T2 values ​​between the two groups.

Conclusion: Deferasirox (Enrige) can significantly reduce SF levels in children with β-TM, and shows dose-dependent changes; it does not show obvious advantages in reducing cardiac iron load, but has a significant effect in reducing liver iron load.

The above is the content of (Enrig) effect, I hope it can help you!

Recommended related hot articles: /newsDetail/80675.html